LENZ THERAPEUTICS, INC. (LENZ) Current Ratio
- Current ratio · latest quarter: Value 13.55×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 13.55× | Current assets / current liabilities. $233.28M ÷ $17.21M ≈ 13.55× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 233.28M USD | Assets, Current |
| Current obligations | 17.21M USD | Liabilities, Current |
| Cash and equivalents | 24.21M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 442.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 4.12M USD | Inventory, Net |
| Payables | 6.65M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $233.28M | $17.21M | $24.21M | (m) | $442.00K | $4.12M | $6.65M | (m) | 13.55× |
| 2026-03-31 | $268.37M | $25.81M | $24.77M | (m) | $343.00K | $3.50M | $10.93M | (m) | 10.40× |
| 2025-12-31 | $301.41M | $21.19M | $25.18M | (m) | $329.00K | $2.94M | $4.17M | (m) | 14.23× |
| 2025-09-30 | $207.00M | $16.32M | $25.40M | (m) | (m) | $949.00K | $4.32M | (m) | 12.69× |
| 2025-06-30 | $213.60M | $10.40M | $37.61M | (m) | (m) | (m) | $2.85M | (m) | 20.54× |
| 2025-03-31 | $197.86M | $8.57M | $23.04M | (m) | (m) | (m) | $3.66M | (m) | 23.09× |
| 2024-12-31 | $211.92M | $10.41M | $20.16M | (m) | $0.00 | $0.00 | $4.26M | (m) | 20.36× |
| 2024-09-30 | $220.70M | $7.71M | $41.05M | $176.06M | (m) | (m) | $2.76M | (m) | 28.63× |
| 2024-06-30 | $199.35M | $8.58M | $84.03M | $112.08M | (m) | (m) | $4.41M | (m) | 23.23× |
| 2024-03-31 | $216.67M | $18.89M | $200.36M | $12.92M | (m) | (m) | $7.13M | (m) | 11.47× |
| 2023-12-31 | $67.24M | $18.51M | $35.14M | (m) | (m) | (m) | $5.71M | (m) | 3.63× |
| 2023-09-30 | $238.78M | $12.54M | $182.99M | $51.00M | (m) | (m) | $3.75M | (m) | 19.05× |
| 2023-06-30 | $251.17M | $12.27M | $128.51M | $118.16M | (m) | (m) | $2.72M | (m) | 20.47× |
| 2023-03-31 | $270.31M | $14.34M | $69.81M | $194.28M | (m) | (m) | $1.99M | (m) | 18.85× |
| 2022-12-31 | $275.37M | $13.04M | $47.73M | $220.50M | (m) | (m) | $2.61M | (m) | 21.11× |
| 2022-09-30 | $298.49M | $13.52M | $56.39M | $235.29M | (m) | (m) | $3.97M | (m) | 22.07× |
| 2022-06-30 | $326.64M | $12.07M | $75.17M | $247.12M | (m) | (m) | $3.62M | (m) | 27.07× |
| 2022-03-31 | $343.76M | $12.77M | $185.07M | $154.11M | (m) | (m) | $3.07M | (m) | 26.93× |
| 2021-12-31 | $381.74M | $12.14M | $376.98M | $0.00 | (m) | (m) | $2.45M | (m) | 31.44× |
| 2021-09-30 | $401.23M | $11.27M | $394.80M | (m) | (m) | (m) | $1.76M | (m) | 35.60× |
| 2021-06-30 | $384.75M | $7.86M | $381.96M | (m) | (m) | (m) | $4.05M | (m) | 48.96× |
| 2020-12-31 | $21.10M | $32.05M | $19.78M | (m) | (m) | (m) | $630.00K | (m) | 0.66× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |